Author

N. Palanisamy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 9 Microbiology· 2 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 11 Organism:human· 10 Assay:bulk RNA-seq· 7 Research Focus:cell type annotation· 7 Research Focus:differential expression· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:drug response / drug discovery· 2 Organism:E. coli· 2

Frequent Co-Authors

S. Carskadon· 9 shared B. Ateeq· 5 shared N. Gupta· 4 shared H. Stricker· 3 shared J. O. Peabody· 3 shared N. S. Gupta· 3 shared P. D. Arachchige· 3 shared V. Bhatia· 3 shared

Activity by Year

2018-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersCancer Biology

S. Carskadon

Mutual co-authors in cluster

Author profile →

12 papers

Recent·Most cited

Role of Adenosine Deaminase in Prostate Cancer Progression

C. Charles, S. M. Lloyd, D. W. B. Piyarathna, J. Gohlke, U. Rasaily, V. Putluri, B. W. Simons, A. Zaslavsky, S. Nallandhighal, N. Palanisamy, N. Navone, J. A. Jones, M. M. Ittmann, N. Putluri, D. R. Rowley, , A. Sreekumar

This study identifies adenosine deaminase (ADA) as a driver of prostate cancer progression and metastasis through metabolomics and in vitro/in vivo experiments.

bioRxiv · Aug 9, 2023 · PreprintCancer Biology

An integrative proteomics approach identifies tyrosine kinase KIT as a novel therapeutic target for SPINK1-positive prostate cancer.

N. Manzar, U. K. Khan, A. Goel, S. Carskadon, N. Gupta, N. Palanisamy, B. Ateeq

The paper identifies KIT as a therapeutic target for SPINK1-positive prostate cancer through integrative proteomics and shows KIT inhibition reduces tumor growth and metastasis.

bioRxiv · Jul 24, 2023Cancer Biology

Transcriptional regulation of Dyskerin via canonical WNT signaling modulates sphingolipid biosynthesis and drives colorectal cancer.

S. Nigam, U. K. Khan, A. Praveen, A. Shendre, S. Carskadon, A. Kapoor, A. Tewari, A. Chandra, N. Palanisamy, B. Ateeq

This study identifies DKC1 as a key regulator in colorectal cancer progression through WNT signaling, showing its role in sphingolipid biosynthesis and proposing ceramides as potential biomarkers.

bioRxiv · Jul 18, 2023 · PreprintCancer Biology

An inducible AraC that responds to blue light instead of arabinose

E. Romano, A. Baumschlager, E. B. Akmeric, N. Palanisamy, M. Houmani, G. Schmidt, M. A. Oeztuerk, L. Ernst, M. Khammash, B. Di Ventura

This paper introduces BLADE, a blue light-inducible AraC variant in E. coli that enables reversible control of gene expression and morphology, and uses it to study gene function and create bacteriographs.

Nature Chemical Biology · Apr 26, 2021Peer-reviewedMicrobiology

Transcriptional network involving ERG and AR orchestrates Distal-Less Homeobox 1 mediated prostate cancer progression.

S. Goel, V. Bhatia, S. Carskadon, N. Gupta, M. Asim, N. Palanisamy, B. Ateeq

The paper identifies a transcriptional network involving ERG, AR, and DLX1 in prostate cancer progression and shows BET inhibitors can target this network.

bioRxiv · Aug 28, 2020Cancer Biology

C-terminal eYFP fusion impairs Escherichia coli MinE function

N. Palanisamy, M. A. Öztürk, B. Di Ventura

This study shows that C-terminal eYFP fusion to MinE impairs its function in Escherichia coli, affecting its ability to displace MinC, stimulate MinD ATPase activity, and bind to the membrane.

Open Biology · May 27, 2020Peer-reviewedMicrobiology

Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization

N. Palanisamy, P. D. Arachchige, S. Carskadon, J. Li, I. Loveless, M. Alhamar, J. O. Peabody, H. Stricker, D. A. Chitale, C. G. Rogers, M. Menon, T. A. Bismar, N. S. Gupta, S. R. Williamson

The paper evaluates molecular heterogeneity in prostate cancer biopsy samples using dual immunohistochemistry and RNA in situ hybridization, finding clonal differences and higher heterogeneity in African American patients.

bioRxiv · Oct 25, 2019Cancer Biology

Therapeutically actionable PAK4 is amplified, overexpressed and involved in bladder cancer progression

D. S. Chandrashekar, B. V. S. K. Chakravarthi, A. D. Robinson, J. C. Anderson, S. Agarwal, S. A. Hodigere Balasubramanya, M.-L. Eich, A. K. Bajpai, S. Davuluri, M. S. Guru, A. S. Guru, G. Naik, D. L. Della Manna, K. K. Acharya, S. Carskadon, , S. Varambally

This study identifies PAK4 amplification and overexpression in bladder cancer and shows PAK4 inhibition reduces tumor growth, with potential for combination therapy.

bioRxiv · Aug 20, 2019Cancer Biology

Pseudogene associated recurrent gene fusion in prostate cancer

B. V. Chakravarthi, P. D. Arachchige, S. Carskadon, S. Kalyana-Sundaram, J. Li, K.-H. H. Wu, D. S. Chandrashekar, J. O. Peabody, H. Stricker, C. Hwang, D. A. Chitale, S. R. Williamson, N. S. Gupta, N. M. Navone, C. Rogers, , N. Palanisamy

The paper identifies and validates a novel gene fusion in prostate cancer involving KLK4 and KLKP1, showing its association with high Gleason grade tumors and potential as a biomarker.

bioRxiv · Jun 11, 2019Cancer Biology

Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole mount radical prostatectomy tissue

Z. Lu, S. Williamson, S. Carskadon, P. D. Arachchige, G. Dhamdhere, D. Schultz, H. Stricker, J. O. Peabody, W. Jeong, D. Chitale, T. Bismar, C. Rogers, M. Menon, N. S. Gupta, N. Palanisamy

bioRxiv · Jun 11, 2019Pathology

Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer

R. Tiwari, N. Manzar, V. Bhatia, A. Yadav, S. Carskadon, N. Gupta, A. Zoubeidi, N. Palanisamy, B. Ateeq

This study shows that androgen deprivation therapy upregulates SPINK1, which enhances cellular plasticity and contributes to poor outcomes in prostate cancer.

bioRxiv · Feb 27, 2019Cancer Biology

Epigenetic silencing of miRNA-338-5p and miRNA-421 drives SPINK1-positive prostate cancer.

V. Bhatia, A. Yadav, R. Tiwari, S. Nigam, S. Goel, S. Carskadon, N. Gupta, A. Goel, N. Palanisamy, B. Ateeq

This study identifies miRNA-338-5p and miRNA-421 as epigenetically silenced in SPINK1-positive prostate cancer, and shows their restoration inhibits oncogenic properties.

bioRxiv · Oct 2, 2018Cancer Biology